Xenogeneic Islet Transplantation of Ad5F35-SOCS1 Infected Islets for Therapy of Diabetes

Abstract

Islet transplantation is the most important approach for treating type I diabetes (T1DM), but the early islet apoptosis limits the therapeutic efficacy. SOCS1 (suppressor of cytokine signaling 1), not only has an effect on cytokine signaling pathway, it is also involved in the regulation of signal transduction pathway in cell apoptosis. The aim of this study was to investigate the effect of overexpression of suppressor of cytokine signaling 1 (SOCS1) in islet grafts. In this paper, the Ad5F35-SOCS1 infected islets were constructed, meanwhile the diabetic mice were established and the xenogenic islet transplantation was performed. After islet transplantation, the blood glucose levels of islet recipients were monitored and the kidney samples were harvested to perform the histological and apoptosis assay. The results showed that the blood glucose was restored in most of the diabetic mice after Ad5F35-SOCS1 infected islets transplantation, and normoglycaemia was maintained for a long time. Furthermore, histological analysis indicated that the infected grafts with overexpression of SOCS1 showed strong insulin secretion function and decreased apoptosis in the early post-transplant period. These results demonstrate that SOCS1 could be the underlying target molecule in islet therapy which has great clinical and practical significance.

Key words

Ad5F35-SOCS1 - islet transplantation - xenogenic transplantation

• References

• 1 Jeker LT, Bour-Jordan H, Bluestone JA. Breakdown in Peripheral Tolerance in Type 1 Diabetes in Mice and Humans. Cold Spring Harbor Perspectives in Medicine 2012; 2
• 2 Declercq J, Kumar A, Van Diepen JA et al. Increased β-Cell Mass by Islet Transplantation and PLAG1 Overexpression Causes Hyperinsulinemic Normoglycemia and Hepatic Insulin Resistance in Mice. Diabetes 2010; 59: 1957-1965
• 3 Narang AS, Mahato RI. Biological and biomaterial approaches for improved islet transplantation. Pharmacol rev 2006; 58: 194-243
• 4 Hogan A, Pileggi A, Ricordi C. Transplantation: current developments and future directions; the future of clinical islet transplantation as a cure for diabetes. Frontiers in bioscience: a journal and virtual library 2008; 13: 1192
• 5 Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069
• 6 Reffet S, Thivolet C. Immunology of pancreatic islet transplantation. Diab metabol 2006; 32: 523-526
• 7 Fenjves ES, Ochoa MS, Gay-Rabinstein C et al. Retrovirally transferred genes inhibit apoptosis in an insulin-secreting cell line: implications for islet transplantation. Cell Transplantation 2004; 13: 489-496
• 8 Grey ST, Longo C, Shukri T et al. Genetic engineering of a suboptimal islet graft with A20 preserves β cell mass and function. J Immunol 2003; 170: 6250-6256
• 9 Contreras JL, Bilbao G, Smyth CA et al. Cytoprotection of pancreatic islets before and soon after transplantation by gene transfer of the anti-apoptotic Bcl-2 gene1. Transplantation 2001; 71: 1015-1023
• 10 Emamaullee JA, Rajotte RV, Liston P et al. XIAP overexpression in human islets prevents early posttransplant apoptosis and reduces the islet mass needed to treat diabetes. Diabetes 2005; 54: 2541-2548
• 11 Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nature immunol 2003; 4: 1169-1176
• 12 Kile B, Alexander W. The suppressors of cytokine signalling (SOCS). Cell Mol Life Sci 2001; 58: 1627-1635
• 13 Qin J, Jiao Y, Chen X et al. Overexpression of suppressor of cytokine signaling 1 in islet grafts results in anti-apoptotic effects and prolongs graft survival. Life sciences 2009; 84: 810-816
• 14 Suo G, Qin J, Zhong C et al. Suppressor of cytokine signaling 1 inhibits apoptosis of islet grafts through caspase 3 and apoptosis-inducing factor pathways in rats. Elsevier; 2010
• 15 Noguchi H. Pancreatic islet transplantation. World J Gastrointestinal Surg 2009; 1: 16
• 16 Nanji SA, Shapiro AMJ. Islet transplantation in patients with diabetes mellitus: choice of immunosuppression. BioDrugs 2004; 18: 315-328
• 17 Gysemans C, Callewaert H, Overbergh L et al. Cytokine signalling in the beta-cell: a dual role for IFNgamma. Biochem Soc ransactions 2008; 36: 328-333
• 18 Takahashi R, Nishimoto S, Muto G et al. SOCS1 is essential for regulatory T cell functions by preventing loss of Foxp3 expression as well as IFN-γ and IL-17A production. J exp med 2011; 208: 2055-2067
• 19 Cottet S, Dupraz P, Hamburger F et al. SOCS-1 protein prevents Janus kinase/STAT-dependent inhibition of β cell insulin gene transcription and secretion in response to interferon-γ. J Biol l Chem 2001; 276: 25862-25870
• 20 Ortis F, Cardozo AK, Crispim D et al. Cytokine-induced proapoptotic gene expression in insulin-producing cells is related to rapid, sustained, and nonoscillatory nuclear factor-κB activation. Mol Endocrinol 2006; 20: 1867-1879
• 21 Ortiz-Muñoz G, Lopez-Parra V, Lopez-Franco O et al. Suppressors of cytokine signaling abrogate diabetic nephropathy. J Am Soc Nephrol 2010; 21: 763-772
• 22 O’Sullivan LA, Liongue C, Lewis RS et al. Cytokine receptor signaling through the Jak–Stat–Socs pathway in disease. Mol immunol 2007; 44: 2497-2506
• 23 Yoshimura A, Naka T, Kubo M. SOCS proteins, cytokine signalling and immune regulation. Nature Rev Immunol 2007; 7: 454-465
• 24 Zhang J, Li H, Yu JP et al. Role of SOCS1 in tumor progression and therapeutic application. Int J Cancer 2012;
• 25 Palmer DC, Restifo NP. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends immunol 2009; 30: 592-602